Ruth Roberts

About Ruth Roberts

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath. A co-founder of ApconiX, Ruth has 25 years of experience in leading roles in drug safety within large pharma. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca. With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.

Discover the Power of Target Safety Assessments in a SOT EHS Webinar

Professor Ruth Roberts, Dr Claire Sadler and Dr Leigh Ann Burns Nass present Target Safety Assessments: Knowledge is Power webinar in a SOT 2020 Exhibitor Hosted Session.  Membership of SOT is not required.  Registration for the webinar is free.  

By |2020-07-02T15:47:19+01:00July 2nd, 2020|Events|Comments Off on Discover the Power of Target Safety Assessments in a SOT EHS Webinar

ApconiX Co-organises British Toxicology Society Meeting

The meeting that ApconiX is co-organising the British Toxicology Society  “Science-led Strategies for Success in Discovery and Development Toxicology” is being rearranged for a date later in 2020 - watch this space for updates! Sponsored by Lonza and AstraZeneca and co-organised by ApconiX, GlaxoSmithKline, Sygnature Discovery and Alderley Park,  the meeting is focused on safety [...]

By |2020-03-19T10:36:26+00:00March 8th, 2020|Events|Comments Off on ApconiX Co-organises British Toxicology Society Meeting

Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity

Abstract: Drug-induced liver injury (DILI) is of significant concern to drug development and regulatory review because of the limited success with existing preclinical models. For developing alternative methods, a large drug list is needed with known DILI severity and toxicity. We augmented the DILIrank data set [annotated using US Food and Drug Administration (FDA) drug [...]

By |2020-03-11T16:00:36+00:00January 16th, 2020|Publications|Comments Off on Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity

Merry Christmas and a Happy New Year

Team ApconiX had a fabulous time at their Christmas party - secret Santa brought tears of laughter and sorrow and the odd gasp!  A few team members went incognito. Wishing everyone a lovely holiday and the very best for the coming year.  Looking forward to a new decade and new challenges.  See you in 2020!

By |2019-12-19T18:42:35+00:00December 19th, 2019|Events|Comments Off on Merry Christmas and a Happy New Year

Professor Ruth Roberts is Speaking at the American Association of Pharmaceutical Scientists

Professor Ruth Roberts, Co-Founder and Director of ApconiX will be speaking at the American Association of Pharmaceutical Scientists (AAPS) on Monday 4th November at 9:00am in a session entitled "Next Generation Technologies in Preclinical Development” chaired by Dr Shraddha Thakkar from the US FDA.  Ruth’s talk is entitled “Science-Driven Design of the Preclinical Package: Case [...]

By |2019-10-30T11:27:07+00:00October 30th, 2019|Events|Comments Off on Professor Ruth Roberts is Speaking at the American Association of Pharmaceutical Scientists

Acuity Target Safety Assessments: Knowledge is Power

A thorough understanding of potential target-related effects is crucial to making the right choices in drug discovery.  Experienced project toxicologists extract and interpret data from mouse knockouts, human gene mutations and known effects of modulators to determine the potential consequences of target inhibition or activation in each organ system. Target Safety Assessments are pivotal in [...]

By |2019-10-01T14:04:36+01:00October 1st, 2019|Target Safety Assessments|Comments Off on Acuity Target Safety Assessments: Knowledge is Power

Dr Kimberly Rockley Presents at the 2019 Gordon Research Conference

Dr Kimberly Rockley and Professor Ruth Roberts had a fabulous time at the Gordon Research Seminar (GRS) and Conference (GRC) earlier this month.  GRCs provide an international forum for the presentation and discussion of cutting-edge research in science; GRSs are organised by and for young investigators and take place alongside the GRC. L to [...]

By |2019-09-04T14:03:05+01:00September 5th, 2019|Events|Comments Off on Dr Kimberly Rockley Presents at the 2019 Gordon Research Conference

Derisking projects: how a focus on TCP (Target – Chemistry – Patient) can help.

We all know drug projects fail – so how can we improve our probability of success? TCP offers a systematic approach to de-risking projects by asking the right questions at the right time around target, chemistry and patient.  For example, T: what are the safety implications of modulating the target?  C: What are the likely [...]

By |2019-08-07T15:17:44+01:00August 7th, 2019|Toxicology|Comments Off on Derisking projects: how a focus on TCP (Target – Chemistry – Patient) can help.

Derivatisation of Parthenolide to Address Chemoresistant Chronic Lymphocytic Leukaemia

Abstract: Parthenolide is a natural product that exhibits anti-leukaemic activity, however, its clinical use is limited by its poor bioavailability. It may be extracted from feverfew and protocols for growing, extracting and derivatising it are reported. A novel parthenolide derivative with good bioavailability and pharmacological properties was identified through a screening cascade based on in [...]

By |2019-08-07T10:14:32+01:00August 6th, 2019|Publications|Comments Off on Derivatisation of Parthenolide to Address Chemoresistant Chronic Lymphocytic Leukaemia

How Alderley Park Grew into an Innovation Hub

A great piece in the Financial Times this week “How Alderley Park Grew into an Innovation Hub” which highlights the success of Alderley Park following AstraZeneca’s announced departure 5 years ago.  Ned Wakeman talks about his team’s continued support of the start-up companies and Dr Chris Doherty explains the vision of the site that will [...]

By |2019-08-01T09:03:51+01:00July 31st, 2019|Press|Comments Off on How Alderley Park Grew into an Innovation Hub